BD Completes Acquisition of Safety Syringes, Inc.

Wed Dec 26, 2012 8:00am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

FRANKLIN LAKES, N.J.,  Dec. 26, 2012  /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company, announced
today that it has completed its acquisition of Safety Syringes, Inc., a
privately held  California-based company that specializes in the development of
anti-needlestick devices for prefilled syringes. The financial terms were not

The acquisition broadens BD's healthcare worker safety offering to include
passive safety technologies for any prefillable syringe customer.  

"We believe the Safety Syringes product line is a valuable asset to BD and
aligns well with our focus on healthcare worker safety, and offering
higher-value products," said Claude Dartiguelongue, President, BD Medical -
Pharmaceutical Systems. "We are excited about this acquisition, which expands
the Company's presence in safety technologies and further demonstrates BD's
commitment to developing innovative solutions that help address our customers'
unmet needs. We are pleased to welcome this new product portfolio and these new
associates to BD."

BD expects the transaction to be minimally dilutive for fiscal year 2013, and
does not expect it to impact BD's previously communicated 2013 earnings

About BD
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world.  BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in  Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please

Colleen T. White, Corporate Communications - 201-847-5369;
Monique N. Dolecki, Investor Relations - 201-847-5378;

SOURCE  BD (Becton, Dickinson and Company)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.